Commentary|Videos|September 11, 2025

How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery

In this video interview, Adrianne Rivard, senior community development manager at myTomorrows, explains why compliance with privacy standards and physician training are critical for safe and effective use of GenAI in clinical trial discovery.

In a recent video interview with Applied Clinical Trials, Adrianne Rivard, senior community development manager, myTomorrows, discussed the challenges physicians face in identifying clinical trials. Highlighting insights from a recent myTomorrows report on the need to streamline clinical operations, Rivard touched on the use of artificial intelligence (AI) to streamline pre-screening, which can reduce the need for multiple databases. She also discussed how AI tools are gaining use, necessitating compliance with data privacy standards and ongoing education to build trust among physicians.

ACT: With nearly a third of physicians now using GenAI tools like ChatGPT to aid in trial discovery, how should clinops teams evaluate and validate the accuracy, compliance, and usability of these emerging technologies?

Rivard: It's great to hear that physicians are starting to use GenAI tools, because I think, like everyone else, they had their initial uncertainty of AI. ‘Can I use this? Can I trust this? How does this work?’ I think especially because physicians are using sensitive data, it's good that they're cautious, but I think for anyone using the tools, or encouraging people to use the tools, really need to make sure that they comply with data privacy standards, regulatory frameworks like HIPAA and GDPR. I think another key factor is education, and we also saw this from the survey, that 69% of physicians said that actual training would build better confidence and trust in the AI, so I think providing ongoing education and support is just as important as the technology itself.


Related to this article

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.